Latest Conference

Learn more about the bidirectional relationship between sleep and waking behaviors.

Learn why awakenings are normal, sleep needs shift with age, and deep sleep protects brain health and cognition.

New research links sleep inertia and daytime sleepiness to dangerous falls in older adults—learn which sleep habits may prevent injuries.

Learn more about sleep issues and their relation to Alzheimer disease.

New research links better NREM sleep to slower Alzheimer disease changes: zolpidem restores brain rhythms, cuts amyloid, and boosts memory in mice models.

Explore the intersections of bipolar disorder with clinical trials and AI.

Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.

Carlos H. Schenck, MD, delivered the keynote address at SLEEP 2026 on REM sleep behavior disorder. Here's what psychiatrists and mental health clinicians need to know.

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.

Discover an objective suicide risk assessment for patients denying ideation, using Suicide Crisis Syndrome and staged warning signs to guide earlier intervention.

Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

APA’s upcoming DSM shifts from “statistical” to “scientific,” adding dimensional, contextual, and biological factors to modernize diagnosis and address past critiques.

After FDA’s new warning, experts stress controlled data show acetaminophen in pregnancy isn’t tied to autism or ADHD; confounding fuels scares.

New evidence shows CBT timed after ketamine boosts lasting depression relief; Yale tests digital therapy Rejoyn to scale the neuroplasticity window.

APA’s next DSM rebrands and adds context, cross-cutting symptoms, and biomarker-ready science to sharpen diagnoses and personalize psychiatric care.

New analysis finds postpartum depression and postpartum psychosis have distinct underlying biological mechanisms.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Review the origins and advancements of ECT.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Phase 2 data suggest luvesilocin quickly eases postpartum depression with durable remission and minimal breast‑milk transfer, supporting larger trials.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Patient selection, monitoring, and counseling on dissociation are critical to safe ketamine treatment.

DT-120, an optimized LSD formulation, shows lasting anxiety relief and high remission at 12 weeks, as researchers share detailed phase 2b safety insights.